📊 ZVRA Key Takeaways
Is Zevra Therapeutics, Inc.. (ZVRA) a Good Investment?
Revenue growth of 350% is severely undermined by deeply negative operating income (-59.1% margin) and negative free cash flow (-2.4M), indicating reported net income is driven by non-operating gains rather than sustainable business operations. The company cannot generate cash from operations despite massive top-line growth, raising critical earnings quality concerns.
Why Buy Zevra Therapeutics, Inc.. Stock? ZVRA Key Strengths
- Exceptional revenue growth of 350.9% year-over-year
- Strong liquidity position with current ratio of 5.68x providing cash runway
- Moderate leverage with debt-to-equity ratio of 0.40x
ZVRA Stock Risks: Zevra Therapeutics, Inc.. Investment Risks
- Negative operating income (-62.9M) with -59.1% operating margin contradicts narrative of profitable growth
- Negative free cash flow (-2.4M) and operating cash flow (-1.6M) despite positive net income signals earnings quality issues and unsustainable one-time gains
- Negative interest coverage ratio (-85.6x) means operating business cannot service 61.9M in long-term debt
Key Metrics to Watch
- Operating cash flow trend and sustainability
- Source and sustainability of non-operating gains inflating net income
- Operating margin improvement required to justify revenue scale
Zevra Therapeutics, Inc.. (ZVRA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.68x current ratio provides a solid financial cushion.
ZVRA Profit Margin, ROE & Profitability Analysis
ZVRA vs Healthcare Sector: How Zevra Therapeutics, Inc.. Compares
How Zevra Therapeutics, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Zevra Therapeutics, Inc.. Stock Overvalued? ZVRA Valuation Analysis 2026
Based on fundamental analysis, Zevra Therapeutics, Inc.. appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Zevra Therapeutics, Inc.. Balance Sheet: ZVRA Debt, Cash & Liquidity
ZVRA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Zevra Therapeutics, Inc..'s revenue has grown significantly by 272% over the 5-year period, indicating strong business expansion. The most recent EPS of $-2.28 indicates the company is currently unprofitable.
ZVRA Revenue Growth, EPS Growth & YoY Performance
ZVRA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $3.7M | -$544.0K | $-0.01 |
| Q2 2025 | $4.4M | -$3.1M | $-0.48 |
| Q1 2025 | $3.4M | -$3.1M | N/A |
| Q3 2024 | $2.9M | -$2.6M | N/A |
| Q2 2024 | $4.4M | -$2.6M | N/A |
| Q1 2024 | $3.2M | -$13.2M | N/A |
| Q3 2023 | $2.9M | -$1.9M | N/A |
| Q2 2023 | $1.3M | -$1.9M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Zevra Therapeutics, Inc.. Dividends, Buybacks & Capital Allocation
ZVRA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Zevra Therapeutics, Inc.. (CIK: 0001434647)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ZVRA
What is the AI rating for ZVRA?
Zevra Therapeutics, Inc.. (ZVRA) has an AI rating of SELL with 87% confidence, based on fundamental analysis of SEC EDGAR filings.
What are ZVRA's key strengths?
Claude: Exceptional revenue growth of 350.9% year-over-year. Strong liquidity position with current ratio of 5.68x providing cash runway.
What are the risks of investing in ZVRA?
Claude: Negative operating income (-62.9M) with -59.1% operating margin contradicts narrative of profitable growth. Negative free cash flow (-2.4M) and operating cash flow (-1.6M) despite positive net income signals earnings quality issues and unsustainable one-time gains.
What is ZVRA's revenue and growth?
Zevra Therapeutics, Inc.. reported revenue of $106.5M.
Does ZVRA pay dividends?
Zevra Therapeutics, Inc.. does not currently pay dividends.
Where can I find ZVRA SEC filings?
Official SEC filings for Zevra Therapeutics, Inc.. (CIK: 0001434647) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ZVRA's EPS?
Zevra Therapeutics, Inc.. has a diluted EPS of $1.35.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ZVRA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Zevra Therapeutics, Inc.. has a SELL rating with 87% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ZVRA stock overvalued or undervalued?
Valuation metrics for ZVRA: ROE of 53.8% (sector avg: 15%), net margin of 78.2% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy ZVRA stock in 2026?
Our dual AI analysis gives Zevra Therapeutics, Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is ZVRA's free cash flow?
Zevra Therapeutics, Inc..'s operating cash flow is $-1.6M, with capital expenditures of $835.0K. FCF margin is -2.3%.
How does ZVRA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 78.2% (avg: 12%), ROE 53.8% (avg: 15%), current ratio 5.68 (avg: 2).
Why is ZVRA's return on equity (ROE) so high?
Zevra Therapeutics, Inc.. has a return on equity of 53.8%, significantly above the Healthcare sector average of 15%. A high ROE indicates the company is efficient at generating profits from shareholder equity. This is supported by a 78.2% net margin.